醫療科技
NEW

柏瑞醫AI秒測骨鬆、肌少症 落地大林慈濟醫院
新聞集錦
NEW

羅氏授權東洋癌症口服標靶藥台灣市場；賽諾菲18億美元攜手AI生物製劑公司Earendil；禮來口服GLP-1新藥三期臨床數據優 股價大漲16%

政策法規
NEW

川普挺小分子藥？ 行政命令擬撤IRA藥價協商「藥丸懲罰」

GBI International
GBIHighlights DigitalPathology TFDA

TFDA certified Jellox Biotech's 'MetaLite DX Digital Pathology Software' as SaMD

2024-01-25/GlobalBio & Investment
BigkudostoJelloxBiotechforreachingasignificantregulatorymilestone!TFDAcertifiedtheir'MetaLiteDXDigitalPathologySoftware'as#SaMD(SoftwareasMedicalDevice)thismonth,markingitthefirstofflineusable...
GBI International
GBIHighlights ADCs Healthcare

The latest progress of ADC drug development in Taiwan

2024-01-25/GlobalBio & Investment
Antibody-drugconjugates(ADCs)featurespecificityandpotentchemotherapy.Sincetheirbreakthroughintreatingsolidtumorsin2019,ADCshavebecomeahotspotforstrategicalliancesandacquisitionsamongpharmaceuticalcomp...
GBI International
GBIHighlights CAR-T Healthcare Biotech celltherapy

The latest progress of six Taiwanese CAR-T therapy developers

2024-01-25/GlobalBio & Investment
GlobalCAR-Tdevelopmentisbustling!AlthoughTaiwanenteredtheCAR-Tfieldlateandfacedhurdleslikepatents,severalcompaniesaretargetingCAR-Tandtakingchallengestomeettheunmetneeds.Theirclinicaltrialsareexpected...
GBI International
GBIHighlights Diabetes TFDA IVD HealthTech

Bio Preventive Medicine Corp.'s DNlite-IVD103 granted TFDA approval

2024-01-25/GlobalBio & Investment
"Bettersafethansorry."CongratulationstoBioPreventiveMedicineCorp.fortheirinnovativekidneydiseasetestkit,DNlite-IVD103,grantedTFDAapproval!Thisbreakthroughbenefitsdiabeticpatientsbypredicting...
GBI International
GBIHighlights Biotech COVID19 Vaccine BIOInsights MVC 蘇益仁

Prof. Ih-Jen Su on Taiwan's biotech industry through the lens of the MVC COVID-19 Vaccine incident

2024-01-25/GlobalBio & Investment
WhatKOLssay:Prof.Ih-JenSuonTaiwan'sbiotechindustrythroughthelensoftheMVCCOVID-19Vaccineincident. ThedevelopmentofCOVID-19vaccineshaspresentedarobustcompetitionmodelforthebiotechindustry.Onlycompan...
GBI International
GBIHighlights

VYSIONEER Collaborates with MC Medical to Introduce the First-ever Brain Tumor Auto Contouring AI

2024-01-25/GlobalBio & Investment
Vysioneer,aleadinginnovatorinOncologyAI,isproudtoannounceastrategiccollaborationwithMCMedical,asubsidiaryofMitsubishiCorporationandawhollyownedsubsidiaryofMCHealthcareHoldingsforbringingadvancedmedica...
GBI International
GBIHighlights

Rockwell Automation is now venturing into Taiwan's biotech industry

2024-01-25/GlobalBio & Investment
EmbracingthefutureofSmartManufacturing(SM),globalindustrialautomationleaderRockwellAutomationisexpandingitsfocustoincludeTaiwan'sbiotechindustry.RecognizingthepivotalroleofTaiwan'sbiopharmaceu...
GBI International
GBIHighlights

From bench to bedside, Prof. Tian-Lu Cheng guides us through the journey of innovation

2024-01-25/GlobalBio & Investment
Frombenchtobedside,Prof.Tian-LuChengguidesusthroughthejourneyofinnovation,startingwithpatentexploration. Navigatingfromthelaboratorytoindustryapplicationsandeventuallytostartups,thepathfrom20innovativ...
GBI International
GBIHighlights

Gene Lay, founder of BioLegend, turned $262,500 into nearly 300 times its value in just a decade

2024-01-25/GlobalBio & Investment
DiscovertheincrediblejourneyofGeneLay,thefounderofBioLegend,whoturnedaninitialinvestmentof$262,500intonearly300timesitsvalueinjustadecade! GeneLaysharedhisentrepreneurialsuccessstoryatthe"2024Bio...
GBI International
GBIHighlights

Bora Expands Globally with $210 Million Acquisition of Upsher-Smith

2024-01-25/GlobalBio & Investment
BreakingNewsinTaiwan!BiotechgiantBoraPharmaceutical(6472-TW)makeswaveswithanotherstrategicmove!Onthe16th,BoraannounceditsfirstU.S.acquisition—Upsher-Smith,acentury-oldpharmaceuticalcompany,atast...
GBI International
GBIHighlights

Meet the startup CEO. Miko Wen

2024-01-25/GlobalBio & Investment
MikoWen,CEOandfounderofTaiwanEarning,atrailblazerincomparativemedicine,isbridgingthegapbetweenhumanandpethealthcare.With96%sharedgenes,dogsplayacrucialroleinunderstandingdiseases.Recentstudieshintatth...
新聞集錦
新聞集錦 投資雷達

01/25《生技股動態》

2024-01-25/新聞中心
市場觀測：✔麗彤(6539)分割暨減資基準日調整為113/3/1 01/25一日漲跌(漲)昱展新藥9.65%、順藥8.37%、智擎4.48%(跌)樂斯科4.95%、上亞科技4.11%、聯合3.96%https://reurl.cc/QeEX0O​01/25三大法人動態(買超)智擎959張、安克371張、昱展新藥204張；(賣超)聯合904張、北極星藥業-KY415張、美時388張https://r...

TOP
  • Global Bio and Investment Monthly
  • 讀者服務電話：+886 2 2726 1065時間：週一 ~ 週五 09:00 ~ 18:00
  • 服務信箱：service@gbimonthly.com
  • 地址：110臺北市信義區信義路六段29號2樓之一, Taiwan

我們的服務